5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology-Reference-Cited by-同舟云学术

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology

Published:2017-09-01 Issue:17 Volume:60 Page:7524-7538
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Beaufils Florent¹,Cmiljanovic Natasa¹,Cmiljanovic Vladimir¹,Bohnacker Thomas¹,Melone Anna¹,Marone Romina¹,Jackson Eileen¹,Zhang Xuxiao²,Sele Alexander¹,Borsari Chiara¹^ORCID,Mestan Jürgen³,Hebeisen Paul³,Hillmann Petra³,Giese Bernd⁴,Zvelebil Marketa¹,Fabbro Doriano³,Williams Roger L.²,Rageot Denise¹,Wymann Matthias P.¹^ORCID

Affiliation:

1. Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland

2. MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, U.K.

3. PIQUR Therapeutics AG, Hochbergerstrasse 60C, 4057 Basel, Switzerland

4. Department of Chemistry, University of Basel, St. Johanns-Ring 19, 4056 Basel, Switzerland

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

http://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.7b00930

Reference44 articles.